Application of population pharmacokinetics to cladribine

BMC Pharmacology

Volumn 5, Issue , 2005, Pages

  Lindemalm, Synnöve ^a   Savic, Radojka M ^b   Karlsson, Mats O ^b   Juliusson, Gunnar ^c   Liliemark, Jan ^a   Albertioni, Freidoun ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cladribine; Clearance; Leukemia; NONMEM; Pharmacokinetic

Indexed keywords

CLADRIBINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CLADRIBINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 26844454904     PISSN: 14712210     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-5-4     Document Type: Article

References (23)

1. Seto S, Carrera J, Kubota M, Wasson B, Carson D: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985, 75:377-383.
2. Liliemark J, Juliusson G: On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 1991, 51:5570-5572.
3. Juliusson G, Liliemark J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992, 79:888-894.
4. Saven A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, Piro LD: Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996, 14:978-983.
5. Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G, Liliemark J: Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clinical Cancer Research 1998, 4:653-658.
6. Albertioni F, Juliusson G, Liliemark J: On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 1993, 44:579-582.
7. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt CM, Evensen SA, Albertioni F, Tjonnfjord GLRLJ: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995, 13:989-995.
8. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters II. Bioexponential model; experimental pharmacokinetic data. J Pharmacokin Biopharm 1981, 9(4):635-653.
9. Lindemalm S, Liliemark J, Juliusson G, Larsson R, Albertioni F: Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 2004, 210:171-177.
10. Gurney H: Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 14:2590-2611.
11. Bleyer WA: A flat dose for all adult [sic] patients. J Clin Oncol 1998, 16:3715.
12. Vriesendorp HM: The next (third) dimension to dosing of anticancer agents. J Clin Oncol 1998, 16:3715-3716.
13. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998, 16:2297-2298.
14. Pinkel D: Cancer chemotherapy and body surface area. J Clin Oncol 1998, 16:3714-3715.
15. Cockcroft DWGHM: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
16. Albertioni F, Pettersson B, Reichelova V, Juliusson G, Liliemark J: Analysis of 2-chloro-2′-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. Ther Drug Monit 1994, 16:413-418.
17. Beal SL, Sheiner LB: NONMEM users guides. University of California, San Fransisco, CA, NONMEM project group; 1992.
18. Jonsson ENKM: Xpose - an S-PLUS population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comp Meth Prog Med 1998, 58:51-64.
19. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR: Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998, 26:207-246.
20. Lindblom L, Ribbing J, Jonsson EN: Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004, 75:85-94.
21. Jonsson ENKM: Automated covariate model building within NONMEM. Pharmaceutical Research 1998, 15:1463-1468.
22. Mandema JW, Verotta D, Sheiner LB: Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992, 20:511-528.
23. Akaike A: Posterior probabilities for choosing a regression model. Annal Instit Math Stats 1979, 30:A9.